Regulatory news and experts insights.

Évaluer le potentiel perturbateur endocrinien d’une substance ne consiste que rarement à examiner une seule étude ou à obtenir un simple résultat positif ou négatif. Le véritable enjeu est d’interpréter l’ensemble des données disponibles : que sait-on déjà de la substance ? Les données existantes permettent-elles d’évaluer de manière adéquate l’activité endocrinienne et les effets indésirables potentiels ? Quelles incertitudes subsistent ? Et surtout, est-il réellement néces

Regulatory compliance rarely involves a single question. Depending on the product, substance and target market, companies may need to address regulatory requirements, toxicological or ecotoxicological data, risk assessment, testing strategies, dossier preparation or ongoing regulatory monitoring.

India’s medical device regulatory framework continues to evolve. The Ministry of Health & Family Welfare has released the Draft Medical Devices (Amendment) Rules, 2026, proposing amendments to the existing Medical Devices Rules, 2017.

Directive (EU) 2026/805 of 30 March 2026 constitutes a major revision of the European Union’s water legislation. By simultaneously amending the Water Framework Directive (2000/60/EC), the Groundwater Directive (2006/118/EC), and the Environmental Quality Standards Directive (2008/105/EC), the text aims to align the protection of water resources with the European Green Deal’s “zero pollution” ambition.

The safety of cosmetic products is generally assessed from the perspective of human health, considering endpoints such as skin irritation, skin sensitisation, systemic toxicity, and endocrine disruption. However, the environmental properties of cosmetic ingredients are becoming increasingly important in substance assessment processes and product development strategies, particularly when selecting formulation ingredients.